HROW News and Press, Harrow Inc Com

A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ ® / AMELIVU ® ) to reference ranibizumab In treatment-naïve patients, SB11 provided functional and anatomical improvements, while BCVA and CST were well ...

NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three studies supporting IHEEZO ® (chloroprocaine HCl ophthalmic gel 3%), a broadly labeled low visc...

2026-07-01 12:32:55 ET More on the markets U.S. Treasury Debt Jumps By $3.1 Trillion Since Passage Of The One Big Beautiful Bill Act Markets Taking A Break After Epic Quarter; Crude Falls S&P 500 Risks Bull Trap As Stronger U.S. Dollar Threatens Q2 Rally ...

NASHVILLE, Tenn., July 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the commercial launch of BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTIS i (ranibizumab) an...

VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability initiatives to ensure dependable supply and remove access barriers VERKAZIA is indicated for the treatment of all forms of vernal keratoconjunctivitis (VKC), a ser...

NASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at William Blair’s 46 th Annual Growth Stock Conference on Wednesday, June 3, 2026, at 8:4...

2026-05-20 04:28:01 ET Harrow ( HROW ) has been an excellent long-term performer, as Harrow moved from a small ophthalmic business with high gross margins to a broader commercial ophthalmology platform with multiple revenue drivers. So the fact that they can grow is established; tod...

2026-05-12 15:43:20 ET Image source: The Motley Fool. Tuesday, May 12, 2026 at 8 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-05-12 14:31:41 ET More on Harrow Health Harrow, Inc. (HROW) Q1 2026 Earnings Call Transcript Harrow: Now Is The Buy Time Harrow: Probably A Short-Term Market Overreaction Harrow prices $50M senior unsecured notes due 2030 at 8.625% Harrow announc...

2026-05-12 14:30:51 ET Harrow, Inc. (HROW) Q1 2026 Earnings Call May 12, 2026 8:00 AM EDT Company Participants Michael Biega - Vice President of Investor Relations & Communications Mark Baum - CEO, Chairman of the Board & Founder Andrew Boll - President, CF...